Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial

Patients with glioblastoma (GBM) have a poor outcome, but even among patients receiving the same therapies and with good prognostic factors, one can find those with exceptionally short and long survival. From the Nordic trial, which randomized GBM patients of 60 years or older between two radiothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Łysiak, Małgorzata, Das, Jyotirmoy, Malmström, Annika, Söderkvist, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452748/
https://www.ncbi.nlm.nih.gov/pubmed/36092918
http://dx.doi.org/10.3389/fgene.2022.934519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452748/
https://www.ncbi.nlm.nih.gov/pubmed/36092918
http://dx.doi.org/10.3389/fgene.2022.934519

Ejemplares similares